3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
15
Neoplasms
4
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Tuberous Sclerosis
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Obesity
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Lymphoma
1
Lung Neoplasms
1
Lung Diseases
1
Kidney Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms, Male
1
Acrocephalosyndactylia
1
Interventions
Radiotherapy
39
pembrolizumab
37
Carboplatin
37
Cisplatin
34
Paclitaxel
26
Pemetrexed
24
Docetaxel
18
Nivolumab
17
Magnetic Resonance Spectroscopy
17
Gemcitabine
17
Bevacizumab
17
Specimen Handling
16
Cyclophosphamide
15
osimertinib
14
Radiation
13
Irinotecan
13
Etoposide
13
Erlotinib Hydrochloride
12
durvalumab
11
Topotecan
10
Cetuximab
10
Radiosurgery
9
Immunoglobulin G
8
Fluorouracil
8
Everolimus
8
Disulfides
8
Celecoxib
8
fludarabine
7
Taxes
7
Ipilimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lung Neoplasms
×
exemestane
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled